KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Restructuring Costs (2016 - 2025)

Historic Restructuring Costs for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $364.9 million.

  • Eli Lilly's Restructuring Costs rose 34718.14% to $364.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $743.9 million, marking a year-over-year increase of 2731.47%. This contributed to the annual value of $860.6 million for FY2024, which is 117119.65% up from last year.
  • Eli Lilly's Restructuring Costs amounted to $364.9 million in Q3 2025, which was up 34718.14% from $35.0 million recorded in Q1 2025.
  • In the past 5 years, Eli Lilly's Restructuring Costs ranged from a high of $435.0 million in Q2 2024 and a low of $35.0 million during Q1 2025
  • For the 5-year period, Eli Lilly's Restructuring Costs averaged around $188.9 million, with its median value being $155.5 million (2021).
  • Its Restructuring Costs has fluctuated over the past 5 years, first surged by 44717.61% in 2021, then tumbled by 6354.07% in 2022.
  • Eli Lilly's Restructuring Costs (Quarter) stood at $104.5 million in 2021, then crashed by 63.54% to $38.1 million in 2022, then surged by 77.69% to $67.7 million in 2023, then soared by 408.12% to $344.0 million in 2024, then rose by 6.08% to $364.9 million in 2025.
  • Its Restructuring Costs was $364.9 million in Q3 2025, compared to $35.0 million in Q1 2025 and $344.0 million in Q4 2024.